pharmaceuticals

  • sam patrick posted an article
    SCBIO believes growing the life sciences sector will significantly transform the state’s economy. see more

    Compliments of the Community Journal...

    It was all smiles on Sept. 30 as BMW marked the 25th anniversary of the first vehicle to roll off its Spartanburg assembly line, a singular moment that dramatically transformed the economic face of South Carolina.

    A quarter-century after opening, the German manufacturer’s North American facility employs more than 11,000 workers who build 1,500 vehicles daily, a pace requiring the services of more than 40 main suppliers across the state.

    The average wage among all S.C. jobs supported by the automotive industry stood at $64,120 in 2017 compared to $40,293 across all employment categories, say findings commissioned by the South Carolina Biotechnology Industry Organization (SCBIO).

    Now three years old, SCBIO is spearheading an aggressive initiative to make South Carolina the preferred location for new or expanding companies in another highly promising industry: life sciences.  Read the entire story by clicking here.

  • sam patrick posted an article
    Lindsay Cobbs named to head KPIC at USC see more

    Compliments of Midlands Biz

    The Kennedy Pharmacy Innovation Center (KPIC) announced that James Lindsay Cobbs has been named chair for the center.

    In his role, Cobbs will focus on creating a regulatory affairs program for students in the College of Pharmacy, including classroom, cocurricular, experiential, and post-graduate opportunities, as well as supporting Nephron Pharmaceuticals in regulatory affairs.

    “My priorities will hone in on developing experiential training opportunities that will enable our students to build skills for both traditional and nontraditional pharmacy roles, developing key partnerships that can support training for our students and to identify ways that will make the College of Pharmacy stand light years apart from other colleges across the country,” says Cobbs.

    Cobbs brings a wide array of career experiences to KPIC, ranging from clinical pharmacy to global policy development in the pharmaceutical industry. After graduating from the UofSC College of Pharmacy in 1992, he launched his career as a staff pharmacist at Johns Hopkins Medical Center. After four years, he entered public service as a regulatory affairs professional at the U.S. Food and Drug Administration (FDA) where he served as regulatory project manager, special assistant and lead project manager in the Office of Compliance and later as associate director for regulatory affairs (ADRA) in the Office of Translational Sciences.

    Cobbs then transitioned to the corporate sector at Janssen Pharmaceuticals, a division of Johnson & Johnson as a policy lead in the Americas, Global Regulatory and Policy Intelligence Department. Cobbs later became the head of US Policy, Global Regulatory Policy and Intelligence for UCB (Union Chimique Belge translated as Union Chemical of Belgium), a multinational biopharmaceutical company headquartered in Brussels, Belgium.

    Cobbs says his various roles have led him to this next challenge. “My experience as a pharmacist at a major teaching institution, working as a public health servant, co-leading drug review teams for novel drug products, and regulatory policy and intelligence in the pharmaceutical industry have prepared me for this unique role,” he says.

    Patti Fabel, Pharm.D. and executive director of KPIC is looking forward to joining efforts with Cobbs. “Our faculty, staff, and students can learn a great deal from him due to his background, experience and skill set,” Fabel says. “He will broaden the scope of what KPIC can offer our students and alumni by developing a regulatory affairs program. I’m excited to see the impact he has on the center and college.”

    Dean Stephen J. Cutler says Cobbs is an exceedingly accomplished expert in pharmaceutical regulatory affairs. “His addition to our faculty will bring added depth and breadth to our educational program as we launch our college’s latest initiative, the Regulatory Affairs Academic Program,” Cutler adds. “This academic program will offer regulatory education to our pharmacy students, provide postgraduate education for residents and fellows, and give another educational track to our graduate program. Our partnership with Nephron Pharmaceuticals will afford us a working laboratory for the development of future pharmacists and scientists serving in regulatory affairs. We are thrilled that Lindsay Cobbs will shepherd this initiative for the College of Pharmacy.”

    Cobbs will begin his role on July 1, 2020.

  • sam patrick posted an article
    Softbox Systems is making its mark globally see more

    Compliments of Upstate Business Journal

    It might not be the first supply chain you think about, but while countries around the world are rushing to find a vaccine for COVID-19, the cold chain behind medical transport is more and more relevant. A company in Greenville, Softbox Systems, has become a global leader in temperature-controlled packaging, helping transport the products of top pharmaceutical companies to hospitals, doctors’ offices and homes around the world.

    Softbox Systems creates packaging — often for the pharmaceutical sector — for different temperature ranges. The packaging is used to transfer individual vials, finished products or active pharmaceutical ingredients from one location to another while keeping the necessary temperature steady for the item. These products can be flu vaccines, EpiPens, inhalers or one of the other countless medications that need to be kept at certain temperatures..

    “If the shipment gets too hot or cold, it can break down molecular properties of said item, and it becomes ineffective,” John Hammes, general manager for the Americas at Softbox Systems explained. “It might work differently with what the intention was, or it may not work at all.”

    Softbox Systems was founded in the U.K. in 1995, and the company maintains its global headquarters there. Hammes started with the company in 2009 to help spearhead U.S. operations since they had been relying on a third party for distribution. The company also has locations in Spain, India, Singapore, Belgium and elsewhere.

    “We had a good product. We knew the industry, so we just put our head down and got to work,” Hammes said. 

    In 2013, the company opened a 29,000-square-foot facility off of Pelham Road in Greenville for its Americas division. Eventually, the company grew too large for that facility and moved to Park Commerce Road in a 65,000-square-foot ISO-certified facility where almost 60 Softbox System employees work.

    While what they do is simple, how they do it isn’t, since medications require different temperatures, Hammes explained. They’ve even worked with Merck Pharmaceuticals on a drone shipper that could be used to transport medicine across disaster areas or war zones, he said. 

    Another product that’s caught people’s attention is  Tempcell ECO — an all paper-based packaging unit launched six months ago that won recognition for innovation by Fast Company. There’s a push, Hammes said, to be more sustainable. 

    Besides developing sustainable products, Softbox Systems also partnered with American Forests. For each Tempcell ECO sold, the company makes a monetary donation to plant a tree. So far, they’ve been able to donate enough to plant more than 20,000 trees. 

    “What we are looking at as a company is to be the global leader not only in temperature control packaging but sustainability,” Hammes said. “We have a corporate drive to do that.”

  • sam patrick posted an article
    Husman launches new quality and compliance consultancy see more

    Dr. David Husman has launched David Husman Consulting, LLC, a company that assists manufacturers with quality and compliance within the pharmaceutical, biopharmaceutical, and biotech industries. Services include quality program development, compliance auditing, remediation, and training.

    Serving as president and principal consultant of the company, Dr. Husman holds a doctorate degree in biochemistry and has more than 30 years of diverse international experience in quality assurance, quality control, and regulatory affairs within the pharmaceutical, biopharmaceutical, and biotech industries. Before beginning David Husman Consulting, he was a principal consultant with Parexel Consulting. He also has served previously in leadership roles in quality assurance, quality control, and regulatory affairs.  

    Dr. Husman is certified in Good Manufacturing Practices and regulatory affairs. He earned his doctorate and bachelor’s degree in biochemistry from The Ohio State University in Columbus, Ohio. He is a long-term member of various professional organizations, including the Regulatory Affairs Professional Society, Parenteral Drug Association, American Society for Quality, and the S.C. Biotechnology Innovation Organization.

    David Husman Consulting began accepting clients as of February 1, 2020. For more information, visit DavidHusmanConsulting.com. 

  • sam patrick posted an article
    Nephron's Lou Kennedy appointed by Governbor to SCRA Executive Committee see more

    SCRA, a public, nonprofit corporation chartered to grow South Carolina’s innovation economy and foster job creation, announced the appointment by Gov. Henry McMaster of Lou Kennedy to the SCRA Board of Trustees’ Executive Committee.

    The nine-member group is comprised of the presidents of Clemson University, the Medical University of South Carolina and the University of South Carolina, the governor or designee (to serve as Chairman), an additional appointee of the governor, the chairman of the House Ways and Means Committee or designee, the chairman of the Senate Finance Committee or designee and two additional members.

    Ms. Kennedy is the president, CEO and owner of Nephron Pharmaceuticals Corporation, a woman-owned business that leads the world in the manufacturing of generic respiratory medications. Kennedy received her Bachelor of Arts in Public Relations from the University of South Carolina. She has received numerous awards in South Carolina and across the country for her achievements in business and leadership. Kennedy is also the immediate past chairman of the S.C. Chamber of Commerce and chairman of the Board of Directors of SCBIO, the state's official life sciences organization.

    “I am excited to welcome Ms. Kennedy to SCRA’s Executive Committee,” said Don Herriott, chairman of the SCRA Board. “Her extensive business and leadership experience has had a tremendous positive impact on South Carolina and makes her a valuable addition to the governing body of SCRA.”

  • sam patrick posted an article
    Alcami's $17 million investment is expected to create 30 new jobs see more

     Alcami Corporation, a leading provider of fully-integrated custom end-to-end solutions for the pharmaceutical and biologics industries, today announced plans to expand the company’s current operations in Charleston County. The $17 million investment is expected to create 30 new jobs.

    Operating in North Charleston since 2001, Alcami offers a variety of solutions tailored to small and midsized pharmaceutical and biotechnology companies.

    Located at 4221 Faber Place Drive in North Charleston, S.C., Alcami will add approximately 6,000 square feet to the footprint of its facility, substantially augmenting the capacity of its sterile drug product development and manufacturing operations.

    The company’s expansion is expected to be completed in 2021. Individuals interested in joining the Alcami team should visit https://www.alcaminow.com/alcami-careers

    The Coordinating Council for Economic Development has approved job development credits related to the project.

    QUOTES

    “The build-out of our Charleston facility comes at a time of rapid growth for Alcami and represents a long-term commitment to our sterile drug product clients, our talented workforce and the greater Charleston area. Our clients expect the most advanced manufacturing technologies and capabilities, and this expansion will ensure we continue to exceed marketplace expectations by remaining on the forefront of industry needs.” -Alcami Site Director Darold Hill

    “When a company like Alcami Corporation continues to invest in our state and our people, it shows the businesses around the world that South Carolina is the place to be. We look forward to seeing this great company continue to grow and thrive for years to come.” –Gov. Henry McMaster

    “We’re excited to see the continued success of Alcami Corporation in Charleston County and the success of our state’s thriving manufacturing industry. We congratulate them on this newest announcement and the creation of 30 new jobs.” –Secretary of Commerce Bobby Hitt

    “The growth of Alcami Corporation during its 18 years in North Charleston has been truly remarkable. This company is a highly-valued corporate citizen, and with this expansion, it is renewing its steadfast and long-standing commitment to our community.” –Charleston County Council Chairman Elliott Summey 

    “We applaud Alcami’s accomplishments in our local economy, building upon their company’s innovation, which is backed by a proven workforce. North Charleston remains ripe for businesses to flourish, and we are always grateful for the benefits our community receives when companies succeed.” –North Charleston Mayor Keith Summey

    “Congratulations to Alcami on announcing their second expansion in Charleston County in the last three years. Assisting local companies in their expansion efforts is a primary focus of our Business Concierge program. Our long-standing relationship with Alcami helped support their decision to grow their global footprint at their North Charleston facility.” –Charleston County Economic Development Executive Director Steve Dykes 

  • sam patrick posted an article
    Biopharma research is an important source of jobs, tax revenue and research spending in SC see more

    New findings show biopharma research companies a source of jobs, tax revenue and research spending in state

     

    GREENVILLE, S.C., October 4, 2018 – This week, the Pharmaceutical Research and Manufacturers of America (PhRMA) released a new report that finds there are more than 572 active clinical trials in the South Carolina, and the life science industry supports 29,500 high-quality jobs and contributes $7.9 billion to South Carolina’s economy. These clinical trials can be responsible for more than half of the $2.6 billion average cost of developing one new medicine. They are investigating some of the biggest health care challenges South Carolinians face, including arthritis, cancer, diabetes, cardiovascular disease, and Alzheimer’s disease.

    The report, titled “Research in Your Backyard: Developing Cures, Creating Jobs, Pharmaceutical Clinical Trials in South Carolina,” was released at a press event held at the Westin Poinsett today, which featured a panel discussion including researchers and executives from the Greenville Health System, KIYATEC, the Hollings Cancer Center at MUSC, and the Greenwood Genetic Center, moderated by SCBIO President and CEO, Sam Konduros.

    “Clinical trials offer patients novel medical treatments right here in the Palmetto State, while also allowing biopharma research organizations to innovate and grow,” said Konduros. “Across South Carolina, the life sciences and healthcare industries have had a profound impact on our economy and citizens, that continues to rapidly increase.”

    Clinical trials are a vital component of bringing new life-saving drugs and treatments to market. On average, it takes approximately a decade for new medicines to go through the rigorous Food and Drug Administration (FDA) approval process. Only 12 percent of drugs successfully make it through clinical trials. Since 2004, biopharmaceutical research companies have conducted or are currently conducting more than 4,700 clinical trials in South Carolina. In 2013 alone, the nearly 1,100 active clinical trials in the state generated an estimated economic impact of $540 million.

    “One of the most important things we want people to understand about medicine development is that clinical trials rely on patient participation,” said Nick McGee, Director of Public Affairs for PhRMA. “It’s incredibly important that patients are aware of ongoing trials and learn how they can help become part of finding a cure for the toughest chronic conditions and diseases we face today.”

    In the United States, there are more than 7,000 open clinical trials being sponsored by the biopharmaceutical industry, universities, individuals and organizations combined. In South Carolina, of the 572 open clinical trials involving the biopharmaceutical research industry, the University of South Carolina Medial School is collaborating on more than 143 clinical trials and the Medical University of South Carolina is collaborating on more than 142.

    “Many top research and medical universities call South Carolina home and are centers of innovation,” Bob Quinn, Executive Director of the South Carolina Research Authority, said. “Maintaining strong partnerships between our universities and life science companies allows us to foster developments right here in South Carolina that can then help save lives far beyond our state lines.”

    You can read the complete report, “Research in Your Backyard: Developing Cures, Creating Jobs, Pharmaceutical Clinical Trials in South Carolina,” here.

    ###

    About PhRMA
    The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading innovative biopharmaceutical research companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier, and more productive lives. Since 2000, PhRMA member companies have invested more than $600 billion in the search for new treatments and cures, including an estimated $71.4 billion in 2017 alone.

    About SC BIO
    SCBIO is South Carolina’s investor-driven public/private economic development organization focused on building, advancing, and growing the life sciences industry in the state.  With an $11.4 billion annual economic impact in the Palmetto State, with more than 400 firms and 15,000 professionals directly involved in the research, development and commercialization of innovative healthcare, medical device, industrial, environmental and agricultural biotech and products that make a difference across the Palmetto State and around the world.  Visit us at SCBIO.org.

  • sam patrick posted an article
    SCBIO 2019 Conference Draws Speakers, Takes Center Stage October 29-31 see more

    Conference registrations soar with sell-out expected; CEOs and top industry leaders from 30 states and countries expected in Greenville for strategic partnership development, industry insights

     

    SOUTH CAROLINA – September 11, 2019Johnson & Johnson Innovation Leader Michal Preminger will join more than 40 additional national speakers at SCBIO 2019 – the annual conference bringing top leaders and executives from life sciences organizations across the state and nation to South Carolina October 29-31.

    Following an October 29 welcome reception showcasing downtown Greenville, Ms. Preminger will address an expected sold-out conference at the Hyatt Regency with a keynote presentation entitled “Innovation for a Better Tomorrow” as the main program gets underway the morning of October 30.  Her presentation will be followed by a high-powered panel comprised of regional healthcare executives entitled “Optimizing the Future of Healthcare in SC and Beyond.” 

    Among other featured Conference programs are EY’sNextWave Wellness:  An Interactive View of the Future of Our Industry”, and an address by South Carolina Lieutenant Governor Pamela Evette entitled “South Carolina:  Just Right for Life Sciences.”  Clemson University President Jim Clements headlines Day 2 with an address entitled “The Power of Partnerships in Fueling Life Sciences”, while Medtronic global executive Christian Howell will address “Driving Value-Based Care Through Collaboration"

    Scores of top industry chief executives, leaders in government and higher education, biotechnology and pharma executives, clinicians and researchers, and industry supporters from across America have already registered to attend SCBIO 2019, with registration nearly doubling the record-setting pace of 2018.  Other committed speakers and panelists include IQVIA Institute of Health Data Science SVP Murray Aitken, Innova Therapeutics CEO and Founder Robert Ryan, ChartSpan CEO & Founder Jon-MIchial Carter, Firststring Research President Dr. Gautam Ghatnekar, Nephron Pharmaceuticals CEO Lou Kennedy, USC President (Ret.) Harris Pastides, PhRMA Senior Regional Director Thomas Hardaway and numerous others.  More than 20 programs will be featured over two days.

    Themed “Ignite The Future!”, the 2+ day conference draws attendees from across America for networking, innovation updates, opportunity discovery, partnership making and strategic discussion.  Committed attendees include officials across a broad spectrum of life sciences industries including medical devices, bio manufacturing, drug discovery, pharmaceuticals, diagnostics and testing, digital health and health IT, bio-ag and more.  Space is limited and advance registration is still available at https://www.scbio.org/cpages/register-now-for-scbio-2019.

    SCBIO is South Carolina’s investor-driven economic development organization exclusively focused on building, advancing, and growing the life sciences industry in the state.  The industry has a $12 billion economic impact in the Palmetto State, with more than 670 firms directly involved and over 43,000 professionals employed directly or indirectly in the research, development and commercialization of innovative healthcare, medical device, industrial, environmental and agricultural biotechnology products. 

    SCBIO 2019 kicks off Tuesday evening October 29 with a Grand Opening Reception for conference registrants, speakers and sponsors at Greenville’s ONE Center, presented by Prisma Health.  Wednesday will feature a complete day of sessions beginning at breakfast and continuing through an evening reception presented by the Greenville Area Development Corp., Greenwood Partnership Alliance and City of Greenville.  The conference will conclude Thursday at lunchtime. 

    “Life sciences is a major driver of South Carolina’s economy, and this conference’s growth is testament to the industry’s surging impact, reach and rapidly rising economic significance in our state and region,” noted SCBIO President and CEO Sam Konduros. “Already accounting for thousands of highly-skilled jobs in the Palmetto State, this sector has tremendous growth potential, and we’re excited to showcase the top companies, research universities and leaders from across our state and country at SCBIO 2019.” 

    Among leading biotech and med-tech industry brands participating in the conference are Nephron Pharmaceutical, BIO, Johnson & Johnson, AVX, PhRMA, Medpoint, AdvaMed, Poly-Med, VWR, Ritedose Corporation, Rhythmlink, SoftBox Systems, ZEUS, Patheon Thermo Fisher and more.  All of South Carolina’s research universities – MUSC, Clemson and the University of South Carolina – are represented, as are major healthcare systems, and economic development entities including the South Carolina Department of Commerce, SCRA, the Upstate SC Alliance, the Charleston Regional Development Alliance, Central Carolina Alliance, Economic Development Partnership and SiMT.

    As the official state affiliate of BIO -- the world's largest trade association representing biotechnology organizations – along with PhRMA and AdvaMed, SCBIO members include academic institutions, biotech companies, entrepreneurial organizations, service providers, thought leaders, economic development organizations and related groups whose members are leading the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products that transform how we heal, fuel and feed the world.  For additional information on SCBIO, visit www.SCBIO.org.

  • sam patrick posted an article
    Life sciences is booming across South Carolina, experts report see more

    Compliments of Greenville Business Magazine

    The economic future of South Carolina is being profoundly impacted by a rising industry sector that has unexpectedly achieved the distinction of becoming the fastest-growing component of the Palmetto State’s knowledge economy.  

    Not automotive, not aerospace, but life sciences—a huge and multifaceted trillion-dollar-plus global industry that averages almost triple the R&D of all others, comprised of multiple segments, including drugs and pharmaceuticals, medical devices and equipment, digital health solutions, research-testing-medical labs, bio-science distribution, bio-ag and other life sciences support organizations.  

    The pharmaceutical segment in the U.S. alone employs approximately 3.5 million people, which exceeds the population of many states. Meanwhile, the medtech and digital health segments also continue to ramp-up dramatically, fueled by innovation and disruptive global trends ranging from the transformation of healthcare delivery to the enormous impact of artificial intelligence.

    According to SCBIO’s just released statewide S.C. Life Sciences Strategic Plan (Version 2.0 covering 2019-2021), an influx of new firms into the Palmetto State coupled with a comprehensive recount effort has surprisingly revealed that the number of life science companies with a presence in the Palmetto State has risen to more than 650—a figure which is over 200 more than were recognized in an initial economic impact study conducted approximately three years ago.  

    That foundational study funded by the state Department of Commerce and SCRA revealed an annual life sciences economic impact now conservatively approaching $12 billion, with more than 43,000 direct and indirect employees receiving wages almost double the state’s average, and an employment growth rate twice that of South Carolina as a whole. Perhaps even more compelling is the fact that life science entities are now present in 43 of 46 SC counties.  

    Established starring players in the Palmetto State’s rapidly evolving life sciences constellation such as Nephron Pharmaceuticals in West Columbia have grown from 400 employees to over 1,100 in the same time frame, with an accompanying capital investment close to $400 million dollars. Long-time South Carolina life science companies such as ZEUS Industrial Products in Orangeburg, Clemson University spin-out Poly-Med Inc., Sumter’s BD and Charleston’s Charles River Laboratories are achieving record employment numbers boosted by a growing global customer base.  

    Concurrently, new South Carolina biotech and medtech industry stars recently coming on line such as Thorne Research in Berkeley County and Arthrex in Anderson County have invested tens of millions of dollars in state-of-the-art facilities and are rapidly ramping up to projected employment levels in the hundreds.  

    Equally encouraging is the fact that scores of highly innovative early-stage life sciences companies like Charleston’s Firststring Research Inc.and Greenville’s Humimic Medical are becoming deeply rooted and committed to building their promising futures in South Carolina. This is a testament to the fact that a robust life sciences industry ecosystem is forming and maturing that not only supports larger scale advanced manufacturing operations, but can also foster and support innovative start-ups and early stage (pre-revenue) companies that must be uniquely bolstered in their early developmental years with a myriad of sophisticated resources, talent and funding sources in order to successfully enter the marketplace.  

    In years past, a multitude of promising, young South Carolina-born companies often left the state in order to obtain crucial funding and unique talent in more established bastions of life sciences such as Boston, the West Coast or even the nearby Research Triangle in North Carolina.  

    Gratefully, South Carolina is becoming a rising destination for both mature and early-stage life science companies that are fueled by all three of our major research universities and their extraordinary life sciences core competencies, renowned institutes such as the Greenwood Genetics Center, medical schools anchoring three major regions, the MUSC and Prisma Health science centers, and major healthcare providers.  

    They are also tapping into a growing bullpen of content experts in the Palmetto State ranging from experienced FDA navigators to reimbursement specialists to intellectual property attorneys and other highly specialized consultants 

    Based on the positive momentum of this burgeoning industry—which is virtually recession-proof and a huge diversification for South Carolina’s economy—hard-fought funding for SCBIO has reached a record high with new members joining forces with the organization on a weekly basis.  

    This crucial fuel is enabling unprecedented life sciences economic development strategies to be successfully mounted in the Palmetto State, including the active recruitment of a new generation of leading-edge life sciences companies into South Carolina from all over the world, in tandem and full alignment with vital state, regional and local partners—with recent economic development missions generating measurable results in Switzerland, Italy, Germany, Dubai (UAE), and across the U.S.  

    To achieve SCBIO’s bold vision of building the nation’s most industry-friendly and innovative life sciences ecosystem and business environment to fuel a knowledge economy in South Carolina, there is much work to be done—and it will be an endless journey. And in some respects, the Palmetto State is still somewhat fledgling as a global player in this complex and ever-changing industry.  However, South Carolina’s progress over the past decade has been nothing short of remarkable, and the opportunities are endless and unlimited. 

    Life sciences is now uniquely igniting and demonstrably contributing to a brilliant future for the state of South Carolina.  Please stay tuned—the best is yet to come. 

  • sam patrick posted an article
    SCBIO and Nephron Pnarma executive Lou Kennedy honored by E&Y see more

    WEST COLUMBIA, S.C., June 28, 2019 /PRNewswire/ -- Ernst & Young (EY) honored Nephron Pharmaceuticals President and CEO Lou Kennedy as Health Care Entrepreneur of the Year for the Southeast on Thursday during a gala at the Coca-Cola Roxy in Atlanta. Kennedy, who is Chairman of the South Carolina Chamber of Commerce and of SCBIO, and a nationwide leader in health care, will now compete for the EY national entrepreneur of the year award in November.

    "I am grateful that EY recognizes the hard work our team does every day to deliver safe, effective and affordable drugs to patients, focusing on opiod-free pain treatment," said Kennedy. "As president of a global leader in life-saving drug manufacturing, I hope this award serves as a reminder that women are leading the fight to improve lives across the country and world, and at Nephron, like so many women-owned businesses, we are just getting started."

    Business leaders consider the EY entrepreneur of the year award to be one of the highest professional honors a business owner can earn. The award identifies leaders of fast-growth companies who are making a difference for their communities and beyond through innovation. 

    Nephron is a certified woman-owned business, as recognized by the National Women Business Owners Corporation (NWBOC), the first certifier of Women Business Enterprises. The certification gives Nephron enhanced visibility and a competitive edge.

    The Nephron workforce is forty-four percent women, holding the majority of all advanced degrees at the company. Additionally, women hold key management roles in various departments throughout Nephron, such as Quality Assurance, Chemistry and Microbiology, Regulatory Compliance, Human Resources, Training, R&D Engineering, and Product Development.

    About Nephron
    Nephron Pharmaceuticals Corporation develops and manufactures safe, affordable generic inhalation solution and suspension products specializing in Blow-Fill-Seal technology. In addition, the company operates an industry-leading 503B Outsourcing Facility division which produces pre-filled sterile syringes and IV bags for hospitals across America, in an effort to alleviate their drug shortage needs. In accordance with the DQSA draft guidance, the company follows cGMP, GDP and all quality expectations. The company has been licensed by the Food and Drug Administration. Nephron received a 2017 ISPE/FOYA innovation award for the high level of automation present throughout the facility. For more information, please visit www.nephronpharm.com.

  • sam patrick posted an article
    Nephron CEO and SCBIO Chair Lou Kennedy interviewed on the growth and success of her organization. see more

    Nephron Pharmaceuticals Corporation, located in West Columbia, South Carolina, is a global leader in manufacturing generic respiratory medications and contract manufacturing. Through its innovative approach to sterile manufacturing, Nephron also provides patients access to affordable, high-quality medications. Nephron’s sterile injectables program helps with the drug shortages that hospital across the country are facing.

    Nephron has grown from 400 employees in 2018 to now over 1,000.  A certified woman-owned business, Nephron is recognized by the National Women Business Owners Corporation (NWBOC), the first certifier of Women Business Enterprises.  CEO Lou Kennedy leads the dyunamic organization as well as chairs SCBIO, the life sciences organization for the Palmetto State.  Enjoy this interview with Lou Kennedy, courtesy of MidlandsBiz:  https://whosonthemove.com/lou-kennedy-nephron-pharmaceuticals/

  • sam patrick posted an article
    Nephron CEO Lou Kennedy honored with national award see more

    Nephron Pharmaceuticals President and CEO Lou Kennedy was honored on Thursday by the National Association of Manufacturers (NAM) with an award for outstanding leadership in manufacturing.  Ms. Kennedy is also the Board Chair of South Carolina's life sciences organization, SCBIO.

    NAM recognized Kennedy at its Manufacturing Institute’s STEP Ahead Women’s Initiative. One of NAM’s largest annual events, the STEP Ahead Award celebrates the achievements of women in manufacturing who inspire the next generation to follow in their footsteps.

    “Nephron is a global leader in pharmaceutical manufacturing, and I am grateful to NAM for recognizing the great work of our team of professionals that delivers safe, effective and affordable medications to patients across the world,” said Kennedy.

    Nephron is a certified woman-owned business, as recognized by the National Women Business Owners Corporation (NWBOC), the first certifier of Women Business Enterprises. The certification gives Nephron enhanced visibility and a competitive edge.

    Nephron’s workforce is forty-four percent women, holding the majority of all advanced degrees at the company. Additionally, women hold key management roles in various departments throughout Nephron, such as Quality Assurance, Chemistry and Microbiology, Regulatory Compliance, Human Resources, Training, R&D Engineering, and Product Development.

     

    About Nephron

    Nephron Pharmaceuticals Corporation develops and manufactures safe, affordable generic inhalation solution and suspension products specializing in Blow-Fill-Seal technology. In addition, the company operates an industry-leading 503B Outsourcing Facility division which produces pre-filled sterile syringes and IV bags for hospitals across America, in an effort to alleviate their drug shortage needs. In accordance with the DQSA draft guidance, the company follows cGMP, GDP and all quality expectations. The company has been licensed by the Food and Drug Administration. Nephron received a 2017 ISPE/FOYA innovation award for the high level of automation present throughout the facility. For more information, please visit www.nephronpharm.com.

  • sam patrick posted an article
    EVENITY Rapidly Reduces Fracture Risk and Builds New Bone With 12 Months of Therapy see more

    Amgen (NASDAQ: AMGN) and UCB (Euronext Brussels: UCB) today announced that the U.S. Food and Drug Administration (FDA) has approved EVENITY™ (romosozumab-aqqg) for the treatment of osteoporosis in postmenopausal women at high risk for fracture. EVENITY is the first and only bone builder with a unique dual effect that both increases bone formation and to a lesser extent reduces bone resorption (or bone loss) to rapidly reduce the risk of fracture. A full course of EVENITY therapy is 12 monthly doses administered by a healthcare provider.2 Since osteoporosis is a chronic disease, continued therapy with an anti-resorptive agent should be considered once EVENITY therapy is completed.

    Click here to read the complete interactive Multichannel News Release... 

  • sam patrick posted an article
    DPX Technologies has invested more than $2.5 million and announced an expansion in Columbia, SC see more

    Columbia, SC – DPX Technologies, a manufacturer of laboratory consumable products, has invested more than $2.5 million and announced an expansion in Columbia, SC. The biotechnology company purchased and renovated a 12,000 sq. ft facility on 5 acres in the SCRA Carolina Research Park.

    DPX manufactures patented sample preparation products and specializes in custom workflows for a diverse client base including clinical, forensic, food safety, and pharmaceutical industries. Their products offer sample preparation solutions that are compatible with semi-automated and fully automated liquid handling systems. This enables high sample throughput and high laboratory efficiency.

    Read on for complete details on this story.

  • sam patrick posted an article
    SCBIO's expanded Board of Directors includes life sciences leaders from across South Carolina see more

    Organization’s Boards spans state, industry segments to provide unique blend of expertise for advancing South Carolina’s life sciences industry

     

    GREENVILLE, SC – February 8, 2019 – Less than two years after initiating a comprehensive relaunch of the state’s official life sciences organization, SCBIO has expanded its Board of Directors for its 501c6 operational entity and added a second 10-member Board for its 501c3 research and educational arm for 2019.  It does so having authored the state’s first-ever life sciences strategic growth plan, conducted an economic impact study validating the contributions of the $11.4 billion industry, tripled revenues and quadrupled membership – all since Spring 2017.

    And according to SCBIO President and CEO Sam Konduros, the best and most exciting days for the industry and organization are still ahead of it.

    “In a state perhaps best known for building BMWs and Boeing Dreamliners, there is a very strong life sciences story brewing as well, creating opportunities to diversify and accelerate growth of our state’s knowledge economy,” said Konduros recently.  He further cited rapid growth of such national and global brands including Nephron Pharmaceuticals, Arthrex, ZEUS, Abbott, Thorne and AVX as just a few examples of the state’s rapidly rising life sciences industry, which currently spans more than 400 companies in 44 counties and employs over 15,000 well-paid associates.

    Leading the policy- and strategy-making efforts of the 501c6 entity of the non-profit organization, the Board of Directors meets regularly to receive updates on SCBIO business objectives, domestic and global initiatives, and to help hone strategies and offer insight.  Nephron Pharmaceuticals Corporation CEO Lou Kennedy will serve as SCBIO’s 2019 Board Chair; Stephanie Yarbrough, Womble Bond Dickinson, LLP as Vice Chair; Michael Rusnak, Medical University of South Carolina Research Foundation as Treasurer; and Josh Ridley of ZEUS as Secretary. 

    Jeff Stover of Haynsworth Sinkler Boyd, PA will serve as Legal Officer; Heather Simmons Jones of the Greenwood Partnership Alliance as Annual Conference Officer; Bryan Davis of Prisma/Greenville Health System’s Office of Innovations as Healthcare/Innovation Officer; Adam Hoots of DPR Construction as Talent/Workforce Officer; and Sam Konduros, President and CEO of SCBIO. 

    Recently added members of the SCBIO Board of Directors are:

    Mike Briggs – President & CEO, Central SC Alliance

    Caroline Brown – Director of External Affairs, Medical University of South Carolina

    Thornton Kirby – President & CEO, South Carolina Hospital Association

    Adam Klonecke – Senior Site Director, Abbott

    Angie Leidinger – VP of External Affairs, Clemson University

    Tom McKenna – Chief Operating Officer, Thorne

    Robert Ryan – CEO & Founder, Innova Therapeutics

    Dave Shalaby – President, Poly-Med, Inc.

    Will Williams – President & CEO, Economic Development Partnership (Aiken)

    Cynthia Young – Dean, Clemson University College of Science

     

    Returning members of the SCBIO Board for 2019 are:

    Mandy Brawley – South Carolina Department of Commerce

    Matthew Couvillion – Wyche Law Firm

    John J. Darby – Johnson & Johnson Services

    Tressa Gardner – SE Institute of Manufacturing & Technology

    Mike Graney – Charleston Regional Development Alliance

    Chad Hardaway – University of South Carolina Office of Economic Engagement

    Will Harms – Blue Cross Blue Shield of SC

    Erica Jackson – K&L Gates

    Marc Metcalf – Upstate SC Alliance

    Kathy Phlegar – Phlegar & Associates

    Christine Dixon Thiesing – SCRA

    Courtney Warren – Marsh & McLennan Agency

     

    Comprising the smaller Board of SCBIO’s 501c3 research and educational arm are Kathryn Becker of Translational Science Solutions; Michael Bolick of Treis Blockchain; Matthew Couvillion of Wyche Law Firm; Shontavia Johnson of Clemson University; Steve Johnson of SCRA; Chris Przirembel, retired Clemson University executive; Shawn Regan of Rhythmlink; Craig Walker of Hitachi Healthcare Americas; Erica Jackson of K&L Gates; and SCBIO CEO Sam Konduros.

    SCBIO is South Carolina’s investor-driven public/private economic development organization exclusively focused on building, advancing, and growing the life sciences industry in the state.  The industry has an $11.4 billion annual economic impact in the Palmetto State, with more than 400 firms directly involved and 15,000 professionals employed in the research, development and commercialization of innovative healthcare, medical device, industrial, environmental and agricultural biotech and products.  The state-wide nonprofit has offices in Greenville, Columbia, and Charleston, and represents companies in advanced medicines, medical devices, diagnostics, IT, and healthcare outcome industries.

    SCBIO is the official state affiliate of BIO -- the world's largest trade association representing biotechnology organizations.  SCBIO members include academic institutions, biotech companies, med-tech companies, entrepreneurial organizations, service providers, thought leaders, economic development organizations and related groups whose members are leading the research and development of innovative healthcare, agricultural, industrial and environmental biotech and med-tech products that will make a difference across the Palmetto State, and around the world.